Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $512.52, indicating a +0.06% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.08%.

Nexus Pharmaceuticals, LLC announced the launch of Tranexamic Acid. This milestone is another step for Nexus in its mission to provide life-saving medication to those who need it most. “We are ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is poised for continued growth, supported by recent FDA approvals, including ALYFTREK for CF patients and JOURNAVX for acute pain. These products ...

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its ...

The program starts on May 1 and will include drugs ranging from Amgen's migraine treatment Aimovig, Vertex Pharmaceutical's cystic fibrosis treatment Kalydeco, and Regeneron's Praluent for high ...

The ASX took a hit on Wednesday, down by 0.41% and snapping a three-day winning streak as risk-off sentiment returned, spooked by a sell-off on Wall Street.

(Image: Freepik) Beauty and personal care product startup Pilgrim has raised Rs 200 crore (approximately $23 million) in a mix of primary ... Family Office (NSFO), Vertex Ventures SEA, Sattva ...

Cycle Pharmaceuticals Limited (Cycle ... Through Cycle Vita, eligible* patients will have access to ?nancial, product and clinical education programs tailored to their needs.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... from the UK’s Medicines and Healthcare products Regulatory Agency for ALYFTREK, a once-daily ...

"It's a lose-lose" situation. Pharmaceutical products have long been spared from trade wars due to the potential harms. But Trump's move to increase tariffs on goods from China, including finished ...